Intended for UK Healthcare Professionals. This website contains promotional content.
Intended for IE Healthcare Professionals. This website contains promotional content.
Report adverse events

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page.

  1. Home >
  2. Medicines >
  3. Overview

Supporting the ambition to leave no patient behind on the path to HCV elimination

VOSEVI® is a triple-action treatment for HCV, and comes backed by evidence from clinical trials, and in real-world settings, in patients who have experienced treatment failure on a DAA regimen.1–3

Here you can find out more about VOSEVI®’s safety profile, as well as the EASL recommendations on treating your DAA-experienced patients.

 

VOSEVI® demonstrated efficacy of 90% or more across HCV genotypes in a real-world setting.3 VOSEVI®’s pan-genotypic efficacy means you can treat with confidence, allowing you to focus on your next patient and the ambition to eliminate HCV.1–3

Mode of action

Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication.

 

Velpatasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication and virion assembly. 

 

Voxilaprevir is an inhibitor of the HCV NS3/4A protease, which is required for viral replication.

Dosing

The recommended dose of VOSEVI® in patients aged 12 years and older and weighing at least 30 kg is one 

400 mg/100 mg/100 mg tablet or two 200 mg/50 mg/50 mg tablets, taken orally, once daily with food.1

Indication

VOSEVI® is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.1

 

VOSEVI® has been specifically tested in adults with HCV who have previously been treated with a DAA regimen.1–3

 

In DAA-experienced chronic HCV patients, VOSEVI® comes with demonstrated efficacy across clinical trials and in the real world, supporting the ambition to leave no patient behind.1–3

You may also like to visit

Clinical trials

Abbreviations:

DAA = direct-acting antiviral; EASL = European Association for the Study of the Liver; HCV = hepatitis C virus; RNA = ribonucleic acid.

References:

  1. VOSEVI® Summary of Product Characteristics.
  2. Bourlière M et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134–2146.
  3. Belperio P et al. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. J Viral Hepat. 2019;26:980–990.

UK-VSV-0090

Date of preparation July 2024